ClariVest Asset Management LLC raised its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 1.6% in the first quarter, HoldingsChannel reports. The institutional investor owned 234,898 shares of the biotechnology company’s stock after purchasing an additional 3,700 shares during the period. ClariVest Asset Management LLC’s holdings in BioCryst Pharmaceuticals were worth $1,913,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Paloma Partners Management Co purchased a new position in BioCryst Pharmaceuticals in the fourth quarter valued at $84,000. Great West Life Assurance Co. Can increased its holdings in BioCryst Pharmaceuticals by 82.7% in the first quarter. Great West Life Assurance Co. Can now owns 13,336 shares of the biotechnology company’s stock valued at $108,000 after buying an additional 6,036 shares in the last quarter. Amalgamated Bank purchased a new position in BioCryst Pharmaceuticals in the fourth quarter valued at $122,000. Summit Securities Group LLC purchased a new position in BioCryst Pharmaceuticals in the first quarter valued at $132,000. Finally, Legal & General Group Plc increased its holdings in BioCryst Pharmaceuticals by 14.5% in the fourth quarter. Legal & General Group Plc now owns 19,315 shares of the biotechnology company’s stock valued at $156,000 after buying an additional 2,453 shares in the last quarter. 91.98% of the stock is owned by institutional investors.
In related news, insider Thomas R. Staab II sold 9,750 shares of the company’s stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $7.65, for a total transaction of $74,587.50. Following the completion of the sale, the insider now owns 134,926 shares of the company’s stock, valued at approximately $1,032,183.90. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Thomas R. Staab II sold 11,750 shares of the company’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $7.81, for a total transaction of $91,767.50. Following the sale, the insider now directly owns 137,176 shares of the company’s stock, valued at approximately $1,071,344.56. The disclosure for this sale can be found here. Insiders have sold 75,000 shares of company stock valued at $583,298 in the last three months. Corporate insiders own 5.20% of the company’s stock.
A number of research analysts have weighed in on BCRX shares. BidaskClub cut shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 28th. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 11th. Barclays boosted their target price on shares of BioCryst Pharmaceuticals from $6.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, April 2nd. JMP Securities boosted their target price on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock a “market outperform” rating in a research note on Tuesday, April 2nd. Finally, Piper Jaffray Companies set a $15.00 target price on shares of BioCryst Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, April 22nd. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. BioCryst Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $9.56.
BCRX stock opened at $3.48 on Friday. The company has a debt-to-equity ratio of 2.38, a current ratio of 1.77 and a quick ratio of 1.76. BioCryst Pharmaceuticals, Inc. has a 52 week low of $2.80 and a 52 week high of $9.95.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.28) EPS for the quarter, hitting analysts’ consensus estimates of ($0.28). The business had revenue of $5.89 million during the quarter, compared to analysts’ expectations of $2.92 million. BioCryst Pharmaceuticals had a negative net margin of 472.12% and a negative return on equity of 223.34%. As a group, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -1.21 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Holdings Lifted by ClariVest Asset Management LLC” was first reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.thestockobserver.com/2019/06/14/biocryst-pharmaceuticals-inc-nasdaqbcrx-holdings-lifted-by-clarivest-asset-management-llc.html.
BioCryst Pharmaceuticals Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
Read More: What is a Lock-Up Period?
Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.